Figure S3.
Panel A shows a bar graph depicting the fold induction of HERPUD1 protein expression. The x-axis labels are Patient 1 and Controls, and the y-axis is labeled Fold Induction with a range from 0 to 30. The bar for Controls is significantly higher than the bar for Patient 1, indicating a higher fold induction in controls. Panel B shows a bar graph depicting the fold induction of HYOU1 protein expression. The x-axis labels are Patient 1 and Controls, and the y-axis is labeled Fold Induction with a range from 0 to 5. The bars for Patient 1 and Controls are similar, indicating no significant difference. Panel C shows a Western blot image for HERPUD1 protein expression in samples treated with DMSO and tunicamycin. The lanes are labeled Patient 1, Control 1, Control 2, and Control 3. The bands for tunicamycin-treated samples are more intense than those for DMSO-treated samples. Panel D shows a Western blot image for HYOU1 protein expression in samples treated with DMSO and tunicamycin. The lanes are labeled Patient 1, Control 1, Control 2, and Control 3. The bands for tunicamycin-treated samples are more intense than those for DMSO-treated samples.
Western blot analyses of tunicamycin-treated dermal fibroblasts from patient 1 and three healthy controls. HDFs were treated with tunicamycin (0.5 µg/ml) or DMSO as a vehicle control for 6 h prior to RNA extraction. (A–D) Relative HERPUD1 (A–C) or HYOU1 (B–D) protein expression levels were normalized to GAPDH and expressed as fold induction. Statistical comparisons were performed using two-sided unpaired Welch’s t tests. Data are shown as individual biological replicates. Statistical significance is indicated as follows: *P < 0.05; ns, not significant. Source data are available for this figure: SourceData FS3.